Is NCT05776641 recruiting in Cambridge, MA?

Yes, NCT05776641 is currently recruiting participants at its Cambridge, MA location. This alzheimer disease clinical trial is actively enrolling qualified participants.

How do I join the alzheimer disease clinical trial in Cambridge?

To join this clinical trial in Cambridge, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Cambridge clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Alzheimer Disease Clinical Trial in Cambridge, MA

About This Alzheimer Disease Study in Cambridge

Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits (amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. Gamma waves are important for memory, and in patients with AD, there are fewer gamma waves in the brain. The Tsai lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. A light and sound device was developed for humans that stimulates the brain at 40Hz that can be used safely at home. The goal of this study is to see if using this device can prevent dementia in people who are at risk for developing Alzheimer's disease.

Sponsor: Massachusetts General Hospital

Who Can Participate

Inclusion Criteria

Between 55 - 90 years of age, inclusive.

Immediate family history of Alzheimer's disease.

Mini-Mental State Exam (MMSE) score of 27 or greater at baseline or expected score range for cognitively normal adjusted for education level.

Clinical Dementia Rating Global Score of 0 at baseline.

Delayed Recall score on the Logical Memory IIa subtest of 8 to 15 at baseline or expected score range for cognitively normal adjusted for education level.

Low serum amyloid levels at baseline.

Elevated fibrillar amyloid using 11C PiB PET at baseline between 20 - 70 CL.

Willing and able to undergo MRI brain and PET brain scans.

Adequate visual and auditory acuity to allow for neuropsychological testing.

Able to comply with neuropsychological testing and other study procedures in opinion of site PI.

Willing and able to complete baseline assessments, and willing to participate in 13-month study protocol.

Willing to provide blood samples at specified timepoints. Willing to consider contributing CSF samples at specified timepoints, if asked.

Exclusion Criteria

MRI contraindications, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body.

High myopia \< -7 diopters, or untreated cataracts that affect vision.

Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol.

For subjects agreeing to undergo lumbar punctures, history of bleeding disorders or laboratory results indicating low platelet levels are exclusionary for the procedure.

Concomitant medications:

Treatment with NMDA antagonists.

For subjects undergoing lumbar puncture, current use of warfarin or similar anti-coagulants is exclusionary for the procedure.

Clinical conditions:

History of seizure or medical diagnosis of epilepsy.

Female subjects who are pregnant or currently breastfeeding.

History of severe allergic or anaphylactic reactions.

Longstanding premorbid history (i.e., longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed.

Neurodegenerative disorder associated with cognitive impairment.

Renal disease.

MR imaging findings such as stroke, tumor, leukoencephalopathy that could preclude meaningful analyses of clinical and imaging data in the opinion of the site PI, such as:

Severe leukoencephalopathy seen on MRI.

Relevant structural abnormality (i.e., normal pressure or obstructive hydrocephalus, hypoxic ischemic lesions, hemorrhages, tumors, malformations).

Cerebral amyloid angiopathy, evidenced by T2\

or other susceptibility weighted-MRI.

Laboratory findings, if known (study does not perform testing) suggestive of systemic illness such as renal disease.

Site investigator's discretion, if s/he feels the subject cannot complete sufficient key study procedures. Exceptions to these guidelines may be considered on a case-by-case basis at the discretion of the Project Director.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Cambridge?

Yes, this clinical trial (NCT05776641) has an active research site in Cambridge, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Alzheimer Disease Treatment Options in Cambridge, MA

If you're searching for alzheimer disease treatment options in Cambridge, MA, this clinical trial (NCT05776641) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Cambridge research site is actively enrolling participants for this clinical trial. You'll receive care from experienced alzheimer disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all alzheimer disease clinical trials near you to find additional studies recruiting in your area.

Alzheimer Disease Clinical Trial in Cambridge, MA

Expert Care in Cambridge

IRB Approved

No-Cost Care

Apply for This Cambridge Location

Why Participate?

Simple Process